Certain subsidiaries of Ortho Clinical Diagnostics, an in vitro diagnostics company, amended their June 30, 2014, credit agreement. The amendment increases the revolving credit facility under the credit agreement by $150 million to an aggregate amount of $500 million and extends the maturity date to Feb. 26, 2026, provided that such date may be accelerated subject to certain circumstances.
According to an 8K filed with the SEC, Barclays Bank is serving as administrative agent and collateral agent for the facility.
